Endothelial cells from cancerous tissues that express the VEGFR-2 (vascular endothelial growth factor receptor-2) start up a cascade of signaling pathways that promote tumor angiogenesis and improve cancer cell proliferation, survival, vascular permeability, and migration. Vascular endothelial growth factor (VEGF) and its receptor are important factors in physiological and pathologic angiogenesis, which has been associated with the growth and development of metastases in ovarian cancer. Through several signaling systems, EGFR (epidermal growth factor receptor) regulates cell growth, proliferation, and death. By using molecular docking drug-likeness models, pharmacokinetic, interaction analysis, and molecular dynamic simulation, the aim is to discover new inhibitors for EGFR and VEGFR-2 kinases. About 16 ligands were obtained from the drug bank and were tested against the 2 kinases by molecular docking mechanism. The compound 3C produced the highest docking score, better drug-likeness score, important pharmacokinetic properties, and strong interaction between 3C and amino acids of the 2 kinases. To evaluate the stability of the EGFR and VEGFR-2 kinases-2C complexes, molecular dynamic simulation was also performed. the stability was investigated by root mean square deviation (RMSD), radius of gyra,tion (Rg), and number of Hydrogen bonds. So, Inhibiting the signaling pathway of proteins that play a crucial role in the growth of cancer may be possible using compound 3C.